AML market to reach $5.25 billion by 2030 as personalized medicine expands

The acute myeloid leukemia market is forecast to grow from $3.97 billion in 2026 to $5.25 billion by 2030, driven by personalized medicine, targeted therapies and more stem cell transplants. North America remained the largest regional market in 2025, while The Business Research Company says new report features are meant to help investors and operators track the category.

Why it matters: - The AML market is moving from broad chemotherapy toward more precise treatment options, which can change outcomes for patients and reshape hospital and drugmaker demand. - Growth in targeted therapy, stem cell transplantation and personalized medicine signals a more specialized and higher-value treatment market. - The shift also points to rising demand for earlier diagnosis, monitoring and supportive care infrastructure.

What happened: - The Business Research Company released its Acute Myeloid Leukemia Global Market Report 2026 on October 29, 2026. - The report pegs the AML market at $3.97 billion in 2026, up from $3.73 billion in 2025. - The report forecasts the market will reach $5.25 billion by 2030. - The report estimates a 6.3% CAGR from 2025 to 2026 and a 7.3% CAGR from 2026 to 2030. - Download a free sample of the acute myeloid leukemia market report. - View the full acute myeloid leukemia market report.

The details: - AML is a blood cancer in which immature white blood cells, called myeloblasts or leukemic blasts, build up in the bone marrow. - That buildup limits the bone marrow’s ability to produce healthy blood cells and can impair immune function. - Historical market growth has been driven by rising AML prevalence, better hospital infrastructure, greater awareness of leukemia therapies, continued use of traditional chemotherapy and improvements in supportive care. - Forecast growth is tied to targeted therapy drugs, more stem cell transplant procedures, new tyrosine kinase inhibitors, ambulatory care center expansion and personalized medicine. - Emerging trends include wider use of targeted AML therapies, more stem cell transplantation, individualized chemotherapy regimens, growth in tyrosine kinase inhibitors and monoclonal antibodies, and stronger emphasis on early diagnosis and monitoring.

Between the lines: - Personalized medicine is becoming a central commercial driver because molecular profiling can match AML patients with treatments based on genetic mutations and biomarkers. - That approach can improve treatment effectiveness while reducing side effects, making precision oncology more attractive to clinicians and developers. - In February 2024, the Personalised Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - North America was the largest regional AML market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and future trend analysis.

What's next: - The market is likely to keep favoring therapies that are more targeted, more personalized and easier to deliver outside traditional inpatient settings. - Growth in early diagnosis and monitoring could become more important as treatment becomes more tailored to patient biology. - Expanded use of ambulatory care centers may shift parts of AML care away from hospitals and toward outpatient settings.

The bottom line: - AML is becoming a faster-growing, more precision-focused oncology market, with personalized medicine and targeted therapies at the center of the next phase of expansion.